IC50 (µM) A2780 MCF7 GLC NCI-H23 NCI-H838 CAMA-1 SW480 HCT8 HCT8 Drug WT CP3 C25 WT MR ADR OxR WT ADR WT WT WT WT WT CisR CDDP 6.4 77.3 30.8 14.2 39.7 14.8 19.3 4.1 7.0 4.3 12.5 12.3 13.5 31.9 126.5 Oxaliplatin 4.0 23.4 43.7 20.4 47.7 32.1 131.5 3.7* 9.6* 13.9 >100 36.4 36.1     BNP3029 3.8 6.5 4.8 2.96 7.08 1.92 2.51 4.3 5.7 2.4 2.2 2.0 1.9 2.73 2.65

Table 5: IC50 (μM) values for cisplatin, oxaliplatin and BNP3029 using a variety of wild-type (WT) and drug-resistant cell lines. A2780/WT: human wild type ovarian cancer cell line; A270/CP3 is A2780 with cisplatin resistance cell line; A2780/C25 is A2780 with oxaliplatin resistance cell line; MCF7/ WT: human wild type breast cancer cell line; MCF7/MR is MCF7 with mitoxantrone resistance cell line; MCF7/ADR is MCF7 with adriamycin resistance cell line; MCF7/ OxR is MCF7 with oxaliplatin resistance cell line; GLC/WT: human wild type small cell lung cancer; GLC/ADR is humanGLC with adriamycin resistance cell line; NCI-H23/ WT: human wild type non-small cell lung cancer (adenocarcinoma); NCI-H838/WT: human wild type non-small cell lung cancer (adenocarcinoma); CAMA-1/WT: human wild type breast cancer (adenocarcinoma); SW480/WT: human wild type colorectal cancer (adenocarcinoma); HCT8/WT: human wild type colorectal cancer (adenocarcinoma); HCT8/CisR: humanHCT8 with cisplatin resistance cell line.